Management of immunosuppression in <scp>post‐transplant</scp> lymphoproliferative disorders treated with <scp>CAR</scp> T cells

Jimkap, Nathacha; El Baroudi, Oussama; Lemoine, Jean; Pievani, Daniele; Pastoret, Cédric; Houot, Roch

doi:10.1111/bjh.19355

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These patients frequently require indefinite prophylactic replacement of immunoglobulins. However, to complicate matters, multiple myeloma can also cause a falsely normal or elevated gammaglobulin level, masking an underlying functional hypogammaglobulinemia (33).…”

Section: Discussionmentioning

confidence: 99%

CAR T-cell therapy and the onco-nephrologist

Salvino,

Mussetti,

Peña

et al. 2024

Front. Nephrol.

View full text Add to dashboard Cite

Cell therapy, specifically the revolutionary chimeric antigen receptor (CAR) T-cell therapy, has transformed the landscape of oncology, making substantial strides in practical treatment approaches. Today, established guidelines for diseases such as lymphomas, myelomas, and leukemias actively advocate the utilization of these once-unconventional therapies. The practical impact of these therapies is underscored by their unparalleled efficacy, reshaping the way we approach and implement treatments in the realm of oncology. However, CAR T-cell therapy, with its performance in anti-tumor aggression through cellular action and inflammatory response, also comes with various adverse events, one of which is kidney injury. Therefore, the management of these side effects is extremely important. The integration of knowledge between oncologists and specialized nephrologists has led to the emergence of a new sub-area of expertise for onco-nephrologists specializing in managing kidney complications from immune effector therapies.

show abstract

Section: Discussionmentioning

confidence: 99%